Geron Corp.’s stock jumped on the announcement that the New England Journal of Medicine published two papers today highlighting the unprecedented disease-modifying ability of its telomerase inhibitor imetelstat in two blood-based disorders.
Geron Corp.’s stock jumped on the announcement that the New England Journal of Medicine published two papers today highlighting the unprecedented disease-modifying ability of its telomerase inhibitor imetelstat in two blood-based disorders.